A recent study indicates that people who stop using blockbuster slimming jabs like Mounjaro or Wegovy may regain lost weight much more quickly than those who halt conventional lifestyle programs.
Research printed in a prominent medical journal shows that while obese individuals often shed a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users purchasing these drugs need to be cognizant of the risk of fast rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about one and a half years.
Comparing Approaches
The research, which examined dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through dieting generally experience a less rapid weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Fast Regain
Nutrition scientists propose the mechanism of the jabs accounts for the accelerated rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 levels far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines advise the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, considering the significant potential of relapse, the therapy should be considered life-long.
This view is echoed by drug manufacturers, who say that the results "emphasize the persistent nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
Individuals who have stopped the medication report a intense return of appetite.
"I experienced a trigger that goes on and you become starving," recalled an individual.
This difficulty is worsened if users have not established lasting dietary or behavioural modifications during therapy.
Growing Interest
Survey data show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among females than males.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle changes.
